Advertisement

Topics

Eisai Inc. Company Profile

04:43 EDT 23rd March 2019 | BioPortfolio

Eisai Inc. was established in 1995 and is ranked among the top-20 U.S. pharmaceutical companies (based on retail sales). The company began marketing its first product in the United States in 1997 and has rapidly grown to become a fully integrated pharmaceutical business with fiscal year 2009 (year ended March 31, 2010) sales of approximately $3.9 billion. Eisai’s areas of commercial focus include neurology, gastrointestinal disorders and oncology/critical care. The company serves as the U.S. pharmaceutical operation of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world.


News Articles [220 Associated News Articles listed on BioPortfolio]

Oncodesign Furthers Its Cooperation with Eisai, Started 12 Years Ago

Signature of a new services agreement on breast cancer with the Japanese pharmaceutical company Eisai This program's objective is to define the clinical positioning strategy of Eisai new compounds...

Eisai's Fycompa Newly Approved by U.S. FDA as Treatment for Partial-Onset Seizures in Pediatric Patients with Epilepsy

TOKYO, Oct 1, 2018 - (JCN Newswire) - Eisai Co., Ltd. announced today that its U.S. subsidiary Eisai Inc. received approval from the U.S. Food and Drug Administration (FDA) for an indication expans...

GARDP, Eisai and Takeda announce partnership in the search for new antibiotics

(Drugs for Neglected Diseases Initiative) The Global Antibiotic Research and Development Partnership (GARDP), Eisai Co., Ltd. (TSE: 4523) ('Eisai') and Takeda Pharmaceutical Company Limited (TSE: 4502...

Eisai commences full-scale operation of new production site

Eisai Co., Ltd. announced that its Chinese subsidiary, Eisai China Inc. (ECI) has commenced full-scale operation of its new Suzhou plant located within the Suzhou Industrial Park, and an opening cere...

Eisai, Takeda and GARDP hunt for new antibiotics

The not-for-profit Global Antibiotic Research and Development Partnership has joined forces with Eisai and Takeda to search for new antibiotics. Under a new agreement the Japanese pharma companies wi...

Chinese drug authority accepts Eisai's NDA for Perampanel to treat partial onset seizures

Eisai Co, Ltd has announced that the National Medical Products Administration of China has accepted for review a New Drug Application for Eisai's antiepileptic drug (AED) perampanel (generic name, pro...

Eisai Presents New Data on Lemborexant for Treatment of Irregular Sleep-Wake Rhythm Disorder in Patients With Alzheimer's Disease

At the 11th Clinical Trials in Alzheimer's Disease ConferenceTOKYO, Oct 26, 2018 - (JCN Newswire) - Eisai Co., Ltd. announced that Eisai presented new data from Study 202, a Phase II evaluation of ...

Eisai's antiepileptic drug receives FDA approval to treat partial-onset seizures in pediatric patients

Eisai Co., Ltd. announced today that its U.S. subsidiary Eisai Inc. received approval from the U.S. Food and Drug Administration for an indication expansion for Eisai's antiepileptic drug Fycompa (per...

Drugs and Medications [7 Associated Drugs and Medications listed on BioPortfolio]

Halaven [eisai inc.]

These highlights do not include all the information needed to use HALAVEN safely and effectively. See full prescribing information for HALAVEN.         HALAVEN (eribulin mesylate) injection, fo...

Hexalen [eisai inc.]

Hexalen

Panretin [eisai inc.]

Panretin gel

Aloxi [eisai inc.]

These highlights do not include all the information needed to use ALOXI safely and effectively. See full prescribing information for ALOXI. ALOXI (palonosetron HCl) Injection for Intravenous Use Initi...

Belviq [eisai inc.]

These highlights do not include all the information needed to use BELVIQ / BELVIQ XR safely and effectively. See full prescribing information for BELVIQ / BELVIQ XR .    BELVIQ (lorcaserin hydrochlo...

PubMed Articles [0 Results]

None

Clinical Trials [6 Associated Clinical Trials listed on BioPortfolio]

Study to Assess the Long-term Safety of Lenvatinib Monotherapy, a Lenvatinib Combination Regimen, or a Comparator Treatment Arm to Cancer Patients in Eisai Sponsored Lenvatinib Trials

This study will be conducted to assess the long-term safety of study drug(s) in participants who are enrolled in Eisai-sponsored lenvatinib studies.

A Clinical Trial to Evaluate the Safety and Efficacy of Fycompa in Subjects With Amyotrophic Lateral Sclerosis (ALS)

This is a pilot trial to test perampanel (Fycompa; Eisai, Inc.) in ALS patients. The investigators will focus on safety and preliminary signs of efficacy. Perampanel is approved by the FDA...

Fasting Study of Rabeprazole Sodium Delayed-Release Tablets 20 mg to Aciphex® Delayed-Release Tablets 20 mg

The objective of this study was to investigate the bioequivalence of Mylan's rabeprazole sodium delayed-release 20 mg tablets to Eisai's Aciphex® delayed-release 20 mg tablets following a...

PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment

On March 17th, 2011, the European Commission issued a marketing authorization valid throughout the European Union (EU) for Eribulin mesylate (Halaven; Eisai Limited), for the treatment of ...

Bioequivalence Study of Raperazole 20mg DR Tabs and PARIET® 20 mg DR Tabs Under Fed Conditions

This is an open-label, randomized, single dose, two-sequence, two-periods crossover study, separated by 7 days washout interval from the first Study Drug Administration. This study is cond...

Companies [14 Associated Companies listed on BioPortfolio]

Eisai GmbH

Auf dem globalen Pharmamarkt zählt Eisai zu den führenden forschungs- orientierten Pharmaunternehmen. Mit innovativen Präparaten für Erkrankungen des Zentralen Nerven- systems sowie im Magen-Darm-...

Eisai Europe Ltd

Eisai is committed to developing and delivering highly beneficial new treatments to help improve the lives of people with epilepsy. The development of AEDs is a major strategic ar...

Eisai Corporation of North America

Eisai Corporation of North America is a wholly-owned subsidiary of Eisai Co., Ltd. and supports the activities of its operating companies in North America. These operating companies include: Eisai Res...

Eisai Europe Limited

Eisai is committed to making further contributions to addressing the diversified needs and improving quality of life of patients with epilepsy. Eisai has three currently marketed treatments in Eur...

Eisai Co., Ltd.

Eisai Co., Ltd. is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Through a global network of research facili...

More Information about "Eisai Inc." on BioPortfolio

We have published hundreds of Eisai Inc. news stories on BioPortfolio along with dozens of Eisai Inc. Clinical Trials and PubMed Articles about Eisai Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Eisai Inc. Companies in our database. You can also find out about relevant Eisai Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...


Corporate Database Quicklinks



Searches Linking to this Company Record